OR WAIT null SECS
December 29, 2024
Article
This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.
December 23, 2024
MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.
December 19, 2024
A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.
December 13, 2024
America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.
December 09, 2024
A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.
November 23, 2024
A recent study suggests ketamine can significantly improve symptoms of PTSD and OCD—but this is based on a review of an insufficient number of randomized controlled trials.
November 22, 2024
Podcast
In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.
September 09, 2024
Video
HCPLive spoke to a healthcare expert who gave his thoughts on the Reagan Udall Foundation for the FDA’s recent meeting to discuss advancing treatments for PTSD.
September 06, 2024
The Reagan Udall Foundation hosted a meeting on PTSD treatment needs, with experts and stakeholders highlighting gaps and potential therapies, including MDMA-assisted therapy.
August 16, 2024
In this episode of Crisis Point, PTSD experts and a trial participant react to the FDA’s decision on MDMA-assisted therapy for PTSD.
